Cost savings of universal decolonization to prevent intensive care unit infection: Implications of the REDUCE MRSA trial

Infection Control and Hospital Epidemiology

Volumn 35, Issue , 2014, Pages S23-S31

  Huang, Susan S ^a   Septimus, Edward ^b   Avery, Taliser R ^c   Lee, Grace M ^c   Hickok, Jason ^d   Weinstein, Robert A ^e   Moody, Julia ^d   Hayden, Mary K ^f   Perlin, Jonathan B ^d   Platt, Richard ^c   Thomas Ray, G ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOSPITAL CORPORATION OF AMERICA   (United States)

^e Cook County Health and Hospitals System ^*  (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE; PSEUDOMONIC ACID;

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; COST CONTROL; DECISION ANALYSIS MODEL; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MATHEMATICAL MODEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; ADULT; BACTEREMIA; CONTROLLED STUDY; CROSS INFECTION; DIAGNOSIS; ECONOMICS; HETEROZYGOTE; HOSPITAL COST; LENGTH OF STAY; MASS SCREENING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NOSE CAVITY; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL INFECTIONS;

ADULT; BACTEREMIA; CARRIER STATE; COST SAVINGS; CROSS INFECTION; HOSPITAL COSTS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MASS SCREENING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NASAL CAVITY; STAPHYLOCOCCAL INFECTIONS;

EID: 84907993447     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1086/677819     Document Type: Article

References (25)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323–2329.
2. United States Government Accountability Office. Healthcare- Associate Infections in Hospitals. Report to the Chairman, Committee on Oversight and Government Reform, House of Representatives, 2008.
3. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol 2011;32:101–114.
4. Lucet JC, Paoletti X, Lolom I, et al. Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med 2005;31:1051–1057.
5. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006;43:971–978.
6. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007;167:2073–2079.
7. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:1155–1161.
8. Huskins WC, Huckabee CM, O’Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011;364:1407–1418.
9. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013;368:2255–2265.
10. Climo M., Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013;368:533–542.
11. Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2013;14:31–39.
12. Perlin JB, Hickok JD, Septimus EJ, Moody JA, Englebright JD, Bracken RM. A bundled approach to reducemethicillin-resistant Staphylococcus aureus infections in a system of community hospitals. J Healthc Qual 2013;35:57–68.
13. Hassan M, Tuckman HP, Patrick RH, Kountz DS, Kohn JL. Cost of hospital-acquired infection. Hosp Top 2010;88:82–89.
14. Roberts RR, Frutos PW, Ciavarella GG, et al. Distribution of variable vs fixed costs of hospital care. JAMA 1999;281:644–649.
15. Nelson RE, Samore MH, Smith KJ, Harbarth S, Rubin MA. Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clin Microbiol Infect 2010;16: 1740–1746.
16. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266–1271.
17. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561–566.
18. Graves N, Weinhold D, Tong E, et al. Effect of healthcareacquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol 2007;28:280–292.
19. Richter SS, Diekema DJ, Heilmann KP, et al. Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States. Antimicrob Agents Chemother 2014;58(2):740-745.
20. Desroches M, Potier J, Laurent F, et al. Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. J Antimicrob Chemother 2013;68(8):1714–1717.
21. Kang J, Mandsager P, Biddle AK, Weber DJ. Cost-effectiveness analysis of active surveillance screening for methicillin-resistant Staphylococcus aureus in an academic hospital setting. Infect Control Hosp Epidemiol 2012;33:477–486.
22. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM. A costbenefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price? Infect Control Hosp Epidemiol 2004;25:418–424.
23. Morgan DJ, Pineles L, Shardell M, et al. The effect of contact precautions on healthcare worker activity in acute care hospitals. Infect Control Hosp Epidemiol 2013;34:69–73.
24. Courville XF, Tomek IM, Kirkland KB, Birhle M, Kantor SR, Finlayson SR. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 2012;33:152–159.
25. Kilgore M, Brossette S. Cost of bloodstream infections. Am J Infect Control 2008;36:S172–S173.